Talis Biomedical (Talis Biomedical) Forward PE Ratio : 0.00 (As of Jun. 09, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Forward PE Ratio?

Talis Biomedical's Forward PE Ratio for today is 0.00.

Talis Biomedical's PE Ratio without NRI for today is 0.00.

Talis Biomedical's PE Ratio for today is 0.00.

Talis Biomedical Forward PE Ratio Historical Data

The historical data trend for Talis Biomedical's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical Forward PE Ratio Chart

Talis Biomedical Annual Data

Trend

Forward PE Ratio

Talis Biomedical Quarterly Data

Forward PE Ratio

Competitive Comparison of Talis Biomedical's Forward PE Ratio

For the Medical Devices subindustry, Talis Biomedical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talis Biomedical's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Forward PE Ratio falls into.

Talis Biomedical Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Talis Biomedical (NAS:TLIS) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Talis Biomedical Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Talis Biomedical (Talis Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (NAS:TLIS) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

3400 Bridge Parkway, Redwood City, CA, USA, 94065

Website

https://talisbio.com

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

Executives

Andrew A Lukowiak	officer: President, other: Chief Scientific Officer	1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich	officer: Interim CFO	CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser	director, officer: President and CEO	561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan	officer: Sr. Vice President, R&D	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063